Hoth Therapeutics’ (HOTH) Buy Rating Reaffirmed at HC Wainwright

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $4.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 194.12% from the company’s previous close.

Other analysts also recently issued reports about the stock. D. Boral Capital reaffirmed a “buy” rating and set a $5.00 price objective on shares of Hoth Therapeutics in a report on Tuesday, January 7th. Benchmark reiterated a “speculative buy” rating and issued a $3.00 target price on shares of Hoth Therapeutics in a research report on Friday, October 11th.

Hoth Therapeutics Stock Performance

NASDAQ HOTH opened at $1.36 on Thursday. Hoth Therapeutics has a 52-week low of $0.58 and a 52-week high of $3.80. The company has a market capitalization of $9.38 million, a P/E ratio of -1.03 and a beta of 0.75. The company has a fifty day moving average of $1.02 and a 200-day moving average of $0.91.

Hoth Therapeutics (NASDAQ:HOTH) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.01). As a group, analysts forecast that Hoth Therapeutics will post -1.18 EPS for the current fiscal year.

Hedge Funds Weigh In On Hoth Therapeutics

An institutional investor recently bought a new position in Hoth Therapeutics stock. Virtu Financial LLC purchased a new stake in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned 0.47% of Hoth Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 7.08% of the company’s stock.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.